肝纤维化新型分子诊断标志物

杜静华; 南月敏

doi:10.3969/j.issn.1001-5256.2017.03.009

肝纤维化新型分子诊断标志物

DOI: 10.3969/j.issn.1001-5256.2017.03.009

河北医科大学第三医院中西医结合肝病科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2596
- HTML全文浏览量: 49
- PDF下载量: 566
- 被引次数: 0
出版历程
- 出版日期: 2017-03-20

Novel molecular diagnostic markers for liver fibrosis

Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University

摘要

摘要: 肝纤维化是各种慢性肝病进展为肝硬化的重要病理阶段,及时准确的评估肝纤维化程度,对指导慢性肝病的治疗具有重要意义。随着分子生物学技术的发展及分子诊断技术在临床的广泛应用,新型血清分子诊断标志物的检测将有助于肝纤维化的早期诊断及精准治疗。近年研究发现并经临床验证有诊断价值的血清新型分子标志物包括成纤维细胞因子、基质金属蛋白酶及其抑制物、细胞外基质相关标志物、非编码RNA等。此外,基因组学、蛋白质组学、代谢组学等分子组学检测亦有诊断意义。
- 肝硬化 /
- 生物学标记 /
- 诊断
Abstract: Liver fibrosis is an important pathological stage for the progression of chronic liver diseases to liver cirrhosis.Timely and accurate assessment of fibrosis degree plays an important role in guiding the treatment of chronic liver diseases.With the development of molecular biology techniques and wide application of molecular diagnostic techniques, the measurement of novel serum molecular diagnostic markers may contribute to the early diagnosis and precise treatment of liver fibrosis.A number of novel serum molecular markers with a diagnostic value have been identified, including fibroblast factor, matrix metalloproteinases and their inhibitors, extracellular matrix-related markers, and non-coding RNAs.In addition, genomics, proteomics, and metabolomics also have certain diagnostic values.
- liver cirrhosis /
- biological markers /
- diagnosis

HTML全文

参考文献(39)

[1]BATALLER R, BRENNER DA.Liver fibrosis[J].J Clin Invest, 2005, 115 (2) :209-218.

[2]PAPASTERGIOU V, TSOCHATZIS E, BURROUGHS AK.Non-invasive assessment of liver fibrosis[J].Ann Gastroenterol, 2012, 25 (3) :218-231.

[3]NEUMAN MG, COHEN LB, NANAU RM.Hyaluronic acid as a non-invasive biomarker of liver fibrosis[J].Clin Biochem, 2016, 49 (3) :302-315.

[4]CALES P, OBERTI F, MICHALAK S, et al.A novel panel of blood markers to assess the degree of liver fibrosis[J].Hepatology, 2005, 42 (6) :1373-1381.

[5]NAN YM, FU N, YU J, et al.Study of the mechanism of rosiglitazone preventing hepatic fibrosis in non-alcoholic steatohepatitis in mice[J].Chin Hepatol, 13 (6) :475-478. (in Chinese) 南月敏, 付娜, 于君, 等.罗格列酮阻止非酒精性脂肪性肝纤维化进展作用机制的研究[J].肝脏, 13 (6) :475-478.

[6]PARK HJ, KIM HG, WANG JH, et al.Comparison of TGF-β, PDGF, and CTGF in hepatic fibrosis models using DMN, CCl4, and TAA[J].Drug Chem Toxicol, 2016, 39 (1) :111-118.

[7]SZABO G, CSAK T.Inflammasomes in liver diseases[J].J Hepatol, 2012, 57 (3) :642-654.

[8]SHOJI, YOSHIO S, MANO Y, et al.Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J].Sci Rep, 2016, 6:28814.

[9]WASMUTH HE, LAMMERT F, ZALDIVAR MM, et al.Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans[J].Gastroenterology, 2009, 137 (1) :309-319.

[10]BERRES ML, TRAUTWEIN C, SCHMEDING M, et al.Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection[J].Hepatology, 2011, 53 (2) :596-603.

[11]WALD O, PAPPO O, SAFADI R, et al.Involvement of the CX-CL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus[J].Eur J Immunol, 2004, 34 (4) :1164-1174.

[12]WEI H, LI B, ZHANG R, et al.Serum GP73, a marker for evaluating progression in patients with chronic HBV infections[J].PLoSOne, 2013, 8 (2) :e53862.

[13]LE P, GAO GS, DONG FB, et al.Serum Golgi protein 73 and three noninvasive serum score systems for diagnosis of liver fibrosis in patients with chronic hepatitis B[J].Chin J Nosocomiology, 2016, 26 (11) :2529-2531. (in Chinese) 乐萍, 高国生, 董飞波, 等.血清高尔基体蛋白73及3种评分系统对慢性乙型肝炎患者肝纤维化的预测价值研究[J].中华医院感染杂志, 2016, 26 (11) :2529-2531.

[14]MUSSO G, GAMBINO R, CASSADER M, et al.Meta-analysis:natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med, 2011, 43 (8) :617-649.

[15]CUSI K, CHANG Z, HARRISON S, et al.Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2014, 60 (1) :167-174.

[16]NIELSEN MJ, KARSDAL MA, KAZANKOV K, et al.Fibrosis is not just fibrosis-basement membrane modelling and collagen metabolism differs between hepatitis B-and C-induced injury[J].Aliment Pharmacol Ther, 2016, 44 (11-12) :1242-1252.

[17]RODERFELD M, HEMMANN S, ROEB E.Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs) [J].Z Gastroenterol, 2007, 45 (1) :25-33.

[18]LICHTINGHAGEN R, HUEGEL O, SEIFERT T, et al.Expression of matrix metalloproteinase-2 and-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C[J].Clin Chem, 2000, 46 (2) :183-192.

[19]KEROLA A, LAMPELA H, LOHI J, et al.Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia[J].J Pathol Clin Res, 2016, 2 (3) :187-198.

[20]LI SL, CAO YN, ZHAO JR, et al.Increased expression of microfibrillar-associated protein 4 in chronic hepatitis B patients[J].Chin J Hepatol, 2012, 20 (6) :474-475. (in Chinese) 李森林, 曹玉宁, 赵景润, 等.微纤维相关蛋白4在慢性乙型肝炎患者肝组织中的表达及其意义[J].中华肝脏病杂志, 2012, 20 (6) :474-475.

[21]MOLLEKEN C, POSCHMANN G, BONELLA F, et al.MFAP4:a candidate biomarker for hepatic and pulmonary fibrosis?[J].Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33 (1) :41-50.

[22]SCHIAVON LL, CARVALHO-FILHO RJ, NARCISO-SCHIA-VON JL, et al.YKL-40-and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCVchronic infection[J].Scand J Gastroenterol, 2010, 45 (5) :615-622.

[23]RATH T, RODERFELD M, GULER C, et al.YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis[J].Scand JGastroenterol, 2011, 46 (11) :1369-1380.

[24]JOHANSEN JS, CHRISTOFFERSEN P, MØLLER S, et al.Serum YKL-40 is increased in patients with hepatic fibrosis[J].J Hepatol, 2000, 32 (6) :911-920.

[25]KAMADA Y, AKITA M, TAKEDA Y, et al.Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis[J].PLoS One, 2013, 8 (6) :e66328.

[26]TAWARA S, TATSUMI T, IIO S, et al.Evaluation of fucosylated haptoglobin and Mac-2 binding protein as serum biomarkers to estimate liver fibrosis in patients with chronic hepatitis C[J].PLoSOne, 2016, 11 (3) :e0151828.

[27]EL-AHWANY E, NAGY F, ZOHEIRY M, et al.Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis[J].Electron Physician, 2016, 8 (1) :1804-1810.

[28]CHEN Q, WU F, WANG M, et al.Transcriptional profiling and miR-NA-Target Network analysis identify potential biomarkers for efficacy evaluation of Fuzheng-Huayu formula-treated hepatitis B caused liver cirrhosis[J].Int J Mol Sci, 2016, 17 (6) :e883.

[29]CERMELLI S, RUGGIERI A, MARRERO JA, et al.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease[J].PLoS One, 2011, 6 (8) :e23937.

[30]RODERBURG C, URBAN GW, BETTERMANN K, et al.MicroRNA profiling reveals a role for miR-29 in human and murine liver fibrosis[J].Hepatology, 2011, 53 (1) :209-218.

[31]NINOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers[J].PLoS One, 2013, 8 (6) :e66086.

[32]ZHANG L, HUANG YL, WANG H, et al.Increased expression of lncRNA AK053349 in peripheral blood mononuclear cells from patients with primary biliary cirrhosis and its clinical significance[J].Int J Lab Med, 2013, 34 (20) :2656-2659. (in Chinese) 张蕾, 黄元兰, 王慧, 等.原发性胆汁性肝硬化患者单个核细胞中lncRNA AK053349表达增高及意义[J].国际检验医学杂志, 2013, 34 (20) :2656-2659.

[33]FU N, NIU X, WANG Y, et al.Role of LncRNA-activated by transforming growth factor beta in the progression of hepatitis C virus-related liver fibrosis[J].Discov Med, 2016, 22 (119) :29-42.

[34]HUANG H, SHIFFMAN ML, CHEUNG RC, et al.Identification o two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C[J].Gastroentrology, 2006, 130 (6) :1679-1687.

[35]XU MY, QU Y, JIA XF, et al.Serum proteomic MRM identify peptide ions of transferrin as new fibrosis markers in chronic hepatitis B[J].Biomed Pharmacother, 2013, 67 (7) :561-567.

[36]BELL LN, THEODORAKIS JL, VUPPALANCHI R, et al.Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (1) :111-120.

[37]CALLEWAERT N, van VLIERBERGHE H, van HECKE A, et al.Noninvasive diagnosis of liver cirrhosis using DNA sequencerbased total serum protein glycomics[J].Nat Med, 2004, 10 (4) :429-434.

[38]TOKUSHIGE K, HASHIMOTO E, KODAMA K, et al.Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease[J].J Gastroenterol, 2013, 48 (12) :1392-1400.

[39]EMBADE N, MARINO Z, DIERCKS T, et al.Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum 1H-NMR spectroscopy[J].PLoS One, 2016, 11 (5) :e0155094.

施引文献

资源附件(0)

访问统计